Advanced Microbiome Interventions (AMI) develops novel therapeutics for Type 1 Diabetes (T1D) and other metabolic and auto-immune diseases. The company is based on research by the two founders, Amsterdam UMC professor Max Nieuwdorp and Wageningen University emeritus professor Willem de Vos.
The number of patients suffering from Type 1 Diabetes and other auto-immune diseases is increasing worldwide and there are strong indications that a causal role is played by the gut microbiome (defined as all microbes and their products residing in the intestinal tract). There is no therapy for treating T1D apart from a life-long use of insulin with many side effects. However, the founders of AMI discovered that specific small molecules produced by the gut microbiome have the capacity to delay the onset of T1D and related symptoms in model systems and patients. AMI will conduct clinical studies of these molecules in cooperation with Amsterdam UMC in order to develop an effective therapy.